MY205498A - Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye - Google Patents

Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Info

Publication number
MY205498A
MY205498A MYPI2020002628A MYPI2020002628A MY205498A MY 205498 A MY205498 A MY 205498A MY PI2020002628 A MYPI2020002628 A MY PI2020002628A MY PI2020002628 A MYPI2020002628 A MY PI2020002628A MY 205498 A MY205498 A MY 205498A
Authority
MY
Malaysia
Prior art keywords
eye
posterior segment
acid
treating diseases
topical composition
Prior art date
Application number
MYPI2020002628A
Other languages
English (en)
Inventor
Nortes Xavier Capdevila
Aquilu Javier Sanagustn
Gan Maria Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of MY205498A publication Critical patent/MY205498A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2020002628A 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye MY205498A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382832 2017-12-04
PCT/EP2018/082999 WO2019110416A1 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Publications (1)

Publication Number Publication Date
MY205498A true MY205498A (en) 2024-10-23

Family

ID=60673756

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002628A MY205498A (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Country Status (24)

Country Link
US (1) US20200390729A1 (https=)
EP (1) EP3720428B1 (https=)
JP (1) JP7846501B2 (https=)
KR (1) KR102756155B1 (https=)
CN (1) CN111542316A (https=)
AU (1) AU2018378981B2 (https=)
BR (1) BR112020011160A2 (https=)
CA (1) CA3083835A1 (https=)
CL (1) CL2020001426A1 (https=)
DK (1) DK3720428T3 (https=)
ES (1) ES2941036T3 (https=)
FI (1) FI3720428T3 (https=)
HR (1) HRP20230319T1 (https=)
HU (1) HUE061852T2 (https=)
MA (1) MA50991B1 (https=)
MX (1) MX2020005809A (https=)
MY (1) MY205498A (https=)
PH (1) PH12020550722A1 (https=)
PL (1) PL3720428T3 (https=)
PT (1) PT3720428T (https=)
SG (1) SG11202004940VA (https=)
SI (1) SI3720428T1 (https=)
WO (1) WO2019110416A1 (https=)
ZA (1) ZA202003944B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300017430A1 (it) * 2023-08-22 2025-02-22 Service Biotech srl Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio
CN117257963B (zh) * 2023-11-02 2024-07-16 广州准优生物科技有限公司 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途
CN117643573B (zh) * 2024-01-29 2024-05-03 天津医科大学眼科医院 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
JP2015500213A (ja) 2011-11-30 2015-01-05 ザイジェン インフラメーション リミテッド 眼乾燥症候群を処置するためのjnkシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
EP2777699B1 (en) 2012-02-02 2017-03-29 Invesfovea S.L. Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration
CA2866405A1 (en) 2012-03-05 2013-09-12 Wayne State University Identification of channelopsin-2 (chop2) mutations and methods of use
RU2014140116A (ru) 2012-04-24 2016-06-10 Тромбодженикс Н.В. Антитела против pdgf-c
EP2875811A1 (en) 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Also Published As

Publication number Publication date
SI3720428T1 (sl) 2023-05-31
CA3083835A1 (en) 2019-06-13
ES2941036T3 (es) 2023-05-16
EP3720428A1 (en) 2020-10-14
WO2019110416A1 (en) 2019-06-13
KR102756155B1 (ko) 2025-01-20
KR20200096569A (ko) 2020-08-12
ZA202003944B (en) 2022-12-21
PH12020550722A1 (en) 2021-02-15
CN111542316A (zh) 2020-08-14
JP7846501B2 (ja) 2026-04-15
HRP20230319T1 (hr) 2023-05-12
CL2020001426A1 (es) 2020-11-06
AU2018378981A1 (en) 2020-07-16
EP3720428B1 (en) 2023-01-11
BR112020011160A2 (pt) 2020-11-17
MX2020005809A (es) 2020-08-20
HUE061852T2 (hu) 2023-08-28
DK3720428T3 (da) 2023-03-20
US20200390729A1 (en) 2020-12-17
JP2021505554A (ja) 2021-02-18
MA50991B1 (fr) 2023-03-31
FI3720428T3 (fi) 2023-03-30
MA50991A (fr) 2020-10-14
PT3720428T (pt) 2023-04-03
PL3720428T3 (pl) 2023-05-08
SG11202004940VA (en) 2020-06-29
AU2018378981B2 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
MX2010003774A (es) Formulaciones oftalmicas acuosas.
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
PH12021550039A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
AU2017261303A1 (en) Ophthalmic compositions
EP4324454A3 (en) Cross-linking agents and associated methods
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MY207444A (en) 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
CA3167959A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
NZ713295A (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
RU2017111579A (ru) Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
AU2020299145A8 (en) Compositions and methods for treating eye diseases